MedTrace Logo

Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC

NCT05000736 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2022-04-29

No results posted yet for this study

Summary

A retrospective cohort study conducted at the Cancer Hospital Chinese Academy of Medical Sciences to compare the effectiveness of palbociclib plus AI therapy and fulvestrant monotherapy as initial endocrine therapy in the patients with HR+/HER2- advanced breast cancer.

Conditions

  • Hormone Receptor Positive Advanced Breast Cancer

Interventions

DRUG

palbociclib + aromatase inhibitor

palbociclib + aromatase inhibitor therapy

DRUG

fulvestrant

fulvestrant monotherapy

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Peng Yuan, M.D. · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-09-01
Completion
2022-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05000736 on ClinicalTrials.gov